Physician profile
Daniel Jennings
NPI 1710596135
$1,696.93
in general payments reported to CMS, 2019-2025
17 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $67.81 · 2023: $554 · 2024: $573 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $288.74 | 2023-2025 | Ozempic, Wegovy |
| Pfizer INC. | $226.78 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $178.48 | 2023-2025 | Lifevest |
| Amgen INC. | $173.33 | 2022-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $120.06 | 2022-2024 | Farxiga, Brilinta |
| Getinge USA Sales, LLC | $116.71 | 2021 | |
| Alnylam Pharmaceuticals INC. | $114.50 | 2023-2024 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $85.37 | 2024-2025 | Eliquis, Camzyos |
| Kestra Medical Technology Services, INC. | $64.84 | 2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $63.94 | 2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $63.35 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.45 | 2022-2024 | Jardiance |
| Bridgebio Pharma, INC. | $37.00 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $34.50 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $26.38 | 2023-2024 | Xarelto |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $24.90 | 2025 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $21.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Jennings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.